Sermorelin vs CJC-1295

At a glance

Evidence grade

Where a compliant provider sells this today

The short answer

Sermorelin and CJC-1295 act on the same receptor. Both are growth-hormone-releasing hormone analogues, both work one step upstream of growth hormone itself, and both leave the pituitary gland in charge of the release.

The differences that matter are not about which receptor. They are about duration, and about how clearly a buyer can tell what is in the vial. Sermorelin is a single molecule with a documented regulatory history. CJC-1295 is a name that covers two molecules, and the one with human trials behind it is often not the one being sold.

Neither compound has been tested against the outcomes adults are buying. Whether either belongs in a given person’s care is a question for a prescriber who knows their history.

The same receptor, a different design goal

Growth-hormone-releasing hormone is the body’s main accelerator for the growth hormone system. Sermorelin is the shortest fragment of it that still carries the activity of the whole molecule. That is its entire design: keep what works, drop the rest.

CJC-1295 starts from the same place and asks a different question. The natural signal is cleared from the blood quickly, and a drug that disappears fast has to be given more often. So the molecule was modified to survive longer.

That is the honest engineering difference between them. It is a difference in how long the signal persists, not in what the signal is or in what the pituitary does with it.

The CJC-1295 naming problem, which has no equivalent on the sermorelin side

This is the single most important difference between these two products, and the consumer market rarely makes it clear.

CJC-1295 was developed with a chemical modification called a drug affinity complex, usually shortened to DAC. The DAC lets the peptide bind to albumin in the blood so it is not cleared quickly, which is what gives it long action. That long-acting version is the one taken into early human trials. Those trials reported sustained increases in growth hormone and IGF-1 after administration. It was never carried through to approval.

What is widely sold under the name CJC-1295 is often labeled "without DAC" or "no DAC". That is not a plainer version of the same product. Remove the DAC and what remains is modified GRF(1-29), a short-acting analogue with a different profile in the body. It is a different molecule wearing the studied molecule’s name.

Sermorelin has no such ambiguity. A vial labeled sermorelin contains the compound the sermorelin literature is about. That is a genuine advantage in interpretability, and it is worth more than most comparisons give it credit for.

What each one has actually been shown to do

Sermorelin provokes a growth hormone response. That property is not contested — it is what an approved diagnostic product was built on. A test that asks whether a pituitary gland can respond only works if the agent reliably makes a working gland respond.

The long-acting CJC-1295 raised growth hormone and IGF-1 in early human work, and did so in a sustained way. That is a genuine pharmacodynamic result.

Both findings are about hormone concentrations in blood. Growth hormone went up. IGF-1 went up. Neither is a demonstration that fat mass, lean mass, sleep quality, recovery time or how a person feels changed, and those are the things being bought.

Duration is a design claim, not an outcome claim

The pitch for CJC-1295 over sermorelin is usually convenience and coverage: a longer-acting signal means a steadier lift and fewer administrations.

The first half is a fair reading of the chemistry. The second half is an assumption about what a steadier lift produces. Nobody has run the trial that compares the two compounds against an outcome a person would notice, so the comparison the marketing makes has never been measured.

There is also a symmetry people miss. A longer-acting signal spends more time overriding the body’s natural pattern of release, which is not obviously an improvement over a shorter one. That is an argument, not a finding, and it is offered here only to show that the convenience case runs in both directions.

Where the regulatory question sits

Sermorelin is not currently marketed in the United States as an FDA-approved product, so what is sold here is compounded. CJC-1295 is not an FDA-approved drug. Neither sits in a settled position, and no outcome, timeline or likelihood is stated here.

A regulatory position changes on its own schedule, and a summary written into a comparison drifts out of date the moment the record moves. Each compound’s status page carries the dated record, and that is where the current position is stated.

Separately, and regardless of any of that: material sold in vials labeled for research use only sits outside the prescription supply chain and carries no assurance of identity, purity, sterility or content. A compounded prescription prepared by a licensed pharmacy for a named patient is a different category of thing. Both circulate under these compound names, and CJC-1295 circulates that way far more heavily than sermorelin does.

How the grades were set

Both are graded limited evidence. Each has a defined receptor target and a documented human effect on growth hormone release, which puts them above compounds resting on cell culture alone. Neither has controlled outcome data for the uses it is sold for, which keeps both short of strong.

One qualification belongs with the CJC-1295 grade and has no counterpart on the sermorelin side. The grade is carried by the studied version, and the studied version is the long-acting DAC form. A buyer holding a vial labeled "no DAC" is holding something with less behind it than the grade implies. Shared branding does not close that gap.

If randomized placebo-controlled trials in adults are published for either compound, its grade moves. Until then, the sharpest practical difference is that one of these names reliably identifies what is in the vial.